Cite

HARVARD Citation

    Fumagalli, C. et al. (2018). The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. Immunotherapy. pp. 1041-1045. [Online]. 
  
Back to record